Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.39 USD | -0.94% | +3.54% | +22.81% |
05-07 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
05-07 | Transcript : Halozyme Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.81% | 5.83B | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Wells Fargo Adjusts Halozyme Therapeutics' Price Target to $55 From $65, Keeps Overweight Rating